The hypertrophic cardiomyopathy phenotype encompasses a heterogeneous spectrum of
genetic and acquired diseases characterized by the presence of left ventricular hypertrophy …

Background Septal reduction therapy (SRT), surgical myectomy or alcohol ablation, is
recommended for obstructive hypertrophic cardiomyopathy (oHCM) patients with intractable …

Pathological cardiac hypertrophy is a key risk factor for the development of heart failure and
predisposes individuals to cardiac arrhythmia and sudden death. While physiological …

Importance There is an unmet need for novel medical therapies before recommending
invasive therapies for patients with severely symptomatic obstructive hypertrophic …

Background: Novel targeted treatments increase the need for prompt hypertrophic
cardiomyopathy (HCM) detection. However, its low prevalence (0.5%) and resemblance to …

Background To simplify surgical septal reduction therapy for hypertrophic obstructive
cardiomyopathy (HOCM), we developed a novel transapical beating-heart septal myectomy …

Background: Septal reduction therapy (SRT) in patients with intractable symptoms from
obstructive hypertrophic cardiomyopathy (oHCM) is associated with variable morbidity and …

Background: In the randomized phase 3 VALOR-HCM study (A Study to Evaluate
Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are …

Background Data assessing the long-term safety and efficacy of mavacamten treatment for
symptomatic obstructive hypertrophic cardiomyopathy are needed. Objectives The authors …

Abstract Purpose of Review We describe the most common phenocopies of hypertrophic
cardiomyopathy, their pathogenesis, and clinical presentation highlighting similarities and …